PHC Holdings Corporation

OTCPK:PHCC.F Stock Report

Market Cap: US$834.8m

PHC Holdings Valuation

Is PHCC.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PHCC.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PHCC.F ($6.28) is trading below our estimate of fair value ($10.27)

Significantly Below Fair Value: PHCC.F is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PHCC.F?

Key metric: As PHCC.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for PHCC.F. This is calculated by dividing PHCC.F's market cap by their current revenue.
What is PHCC.F's PS Ratio?
PS Ratio0.3x
SalesJP¥360.94b
Market CapJP¥125.25b

Price to Sales Ratio vs Peers

How does PHCC.F's PS Ratio compare to its peers?

The above table shows the PS ratio for PHCC.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.7x
FNA Paragon 28
3.5x14.0%US$863.2m
CBLL CeriBell
17.2x23.8%US$1.0b
OFIX Orthofix Medical
1x6.2%US$746.3m
BFLY Butterfly Network
9.2x17.2%US$701.0m
PHCC.F PHC Holdings
0.3x1.4%US$125.2b

Price-To-Sales vs Peers: PHCC.F is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (7.7x).

Price to Sales Ratio vs Industry

How does PHCC.F's PS Ratio compare vs other companies in the US Medical Equipment Industry?

51 CompaniesPrice / SalesEstimated GrowthMarket Cap
Industry Avg.3.4x8.3%
PHCC.F PHC Holdings
 0.3x1.4%US$834.79m
INGN Inogen
0.7x4.2%US$231.28m
ARAY Accuray
0.5x5.5%US$224.26m
PHCC.F 0.3xIndustry Avg. 3.4xNo. of Companies50PS03.26.49.612.816+
51 CompaniesEstimated GrowthMarket Cap
Industry Avg.3.4x17.1%
PHCC.F PHC Holdings
 0.3x41.4%US$834.79m
No more companies

Price-To-Sales vs Industry: PHCC.F is good value based on its Price-To-Sales Ratio (0.3x) compared to the US Medical Equipment industry average (3.4x).

Price to Sales Ratio vs Fair Ratio

What is PHCC.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PHCC.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate PHCC.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PHCC.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$6.84
0%
11.2%US$7.92US$5.74n/a6
Nov ’25US$6.80
US$7.53
+10.7%
6.8%US$8.43US$6.88n/a6
Oct ’25n/a
US$7.53
0%
6.8%US$8.43US$6.88n/a6
Sep ’25n/a
US$7.43
0%
6.8%US$8.32US$6.79n/a6
Aug ’25n/a
US$6.75
0%
8.5%US$7.64US$5.79n/a6
Jul ’25US$7.27
US$6.88
-5.4%
10.4%US$7.59US$5.44n/a7
Jun ’25n/a
US$7.02
0%
10.9%US$7.65US$5.48n/a7
May ’25n/a
US$7.78
0%
10.0%US$9.08US$6.48n/a7
Apr ’25US$8.10
US$8.20
+1.2%
14.8%US$10.55US$6.59n/a7
Mar ’25n/a
US$9.43
0%
20.2%US$13.34US$7.34n/a7
Feb ’25n/a
US$10.90
0%
16.9%US$13.80US$8.28n/a7
Jan ’25n/a
US$11.16
0%
16.6%US$14.19US$8.51n/a7
Dec ’24n/a
US$11.00
0%
13.0%US$13.38US$8.70n/a7
Nov ’24n/a
US$11.10
0%
12.6%US$13.35US$8.68US$6.807
Oct ’24n/a
US$11.50
0%
13.6%US$13.65US$8.87n/a7
Sep ’24n/a
US$11.50
0%
13.6%US$13.65US$8.87n/a7
Aug ’24n/a
US$12.18
0%
12.7%US$14.49US$9.89n/a7
Jul ’24n/a
US$12.68
0%
17.2%US$17.22US$10.05US$7.277
Jun ’24US$11.25
US$12.68
+12.7%
17.2%US$17.22US$10.05n/a7
May ’24n/a
US$13.25
0%
15.7%US$17.45US$10.91n/a7
Apr ’24n/a
US$13.82
0%
14.8%US$17.59US$11.00US$8.107
Mar ’24n/a
US$13.82
0%
14.8%US$17.59US$11.00n/a7
Feb ’24n/a
US$16.29
0%
20.4%US$22.95US$12.24n/a7
Jan ’24n/a
US$16.00
0%
20.1%US$22.18US$11.83n/a7
Dec ’23n/a
US$15.62
0%
19.6%US$21.57US$11.87n/a7
Nov ’23n/a
US$14.91
0%
16.4%US$18.91US$11.55n/a7

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Elevance Health

US$93.4b

Operates as a health benefits company in the United States.

ELV

US$402.75

7D

0.05%

1Y

-16.6%

Lantheus Holdings

US$6.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$90.27

7D

-0.3%

1Y

22.3%

Sensus Healthcare

US$141.0m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

SRTS

US$8.60

7D

-3.3%

1Y

253.9%